OrbiMed Entities Acquire 5M ACET Shares in Registered Offering
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
OrbiMed-related entities reported purchases of Adicet Bio (ACET) common stock on 10/08/2025. The filings show two registered direct offering purchases: 1,500,000 shares at $1 and 3,500,000 shares at $1, increasing combined holdings across affiliated OrbiMed funds and GP vehicles to 9,026,359 and 4,490,254 shares in specific accounts, with additional holdings noted across other funds. The report lists multiple OrbiMed entities and explains their record ownership and GP relationships, while each entity disclaims direct beneficial ownership except to the extent of pecuniary interest. The Form 4s are signed by Carl L. Gordon on 10/10/2025.
Positive
- Large institutional purchase of 5,000,000 shares at $1 indicates material capital commitment
- Transparent disclosure of record holders, GP relationships, and customary disclaimers clarifies voting/investment structure
Negative
- Layered ownership structure via multiple funds makes direct beneficial ownership and control less immediately clear
- No forward intent disclosed beyond the purchases, so investor implications are uncertain
Insights
OrbiMed significantly increased position via a registered direct offering totaling 5,000,000 shares at $1.
Multiple affiliated OrbiMed funds purchased a combined 5,000,000 shares on 10/08/2025, which materially raises their reported holdings in different record accounts to the single-digit millions of shares shown. The ownership structure is layered through general partners and funds, and the filing provides the standard disclaimers that voting and investment power may be exercised through committees while individuals disclaim direct beneficial ownership.
The primary risk for investors is limited: these are purchases disclosed under Section 16 and do not by themselves change company operations. Monitor any subsequent Form 13D/G filings or additional Form 4 activity within the next 30 to 90 days for evidence of further accumulation or a coordinated ownership intent.
Insider Trade Summary
Net Buyer: 5,000,000 shares ($5,000,000)
Net Buy
5 txns
Insider
ORBIMED ADVISORS LLC, OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP Limited Partnership
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
5,000,000 shs ($5.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,500,000 | $1.00 | $1.50M |
| Purchase | Common Stock | 3,500,000 | $1.00 | $3.50M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 9,026,359 shares (Indirect, See footnotes)
Footnotes (1)
- These securities were purchased in an underwritten registered direct offering. These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP. These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by Genesis and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by Genesis. Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
FAQ
What did OrbiMed purchase in the ACET Form 4 filings?
Affiliated OrbiMed funds purchased a total of 5,000,000 common shares on 10/08/2025 via a registered direct offering at $1 per share.
Who signed the Form 4 filings for ACET?
The filings are signed by Carl L. Gordon in various capacities for the OrbiMed reporting entities on 10/10/2025.
Were these purchases part of a rule 10b5-1 plan or similar?
The filings indicate the purchases were made in an underwritten registered direct offering; no 10b5-1 plan is asserted in the disclosed explanation.
Do the filings show OrbiMed intends to control Adicet Bio (ACET)?
No controlling intent is disclosed; the filings include standard disclaimers that the entities may be deemed to have voting or investment power but disclaim direct beneficial ownership except for pecuniary interest.